1597
the best indicator of the efficacy of mean energy losses enzyme preparation:
patients total
In our the high
pancreatin replacement. were no
greater
on
expression after centifugation culture. Cells from seropositive and seronegative healthy donors and allograft recipients with or without CMV disease were used as controls. CMV infection was detected in mononuclear cells of only 1 of 21 healthy donors. Remarkably, in common variable immunodeficiency, CMV DNA was found in most patients and centrifugation culture supported the existence of CMV
acute
antigenaemia:
*Digestibility of total energy (as creon, pancrease HL). This study suggests that a considerable reduction in daily capsule intake can be achieved if the high enzyme preparation is used and this is welcomed by patients. The mean daily dose required was 2-8 to 1, close to the calculated ratio of 3 to 1. The variation in individual requirements means that this 1-for-3 advice is a guideline only; the ideal level of supplementation can be defined by the cumbersome and unpopular fat-balance studies (the limitations of which have been exposed by Murphy et all and confirmed by our own figures) or by patient satisfaction. All the patients in this study chose to continue on the high enzyme product.
(X2) versus healthy donors. ISH=m-situ DNA hybridisation with a CMV probe plasmid pCM 5018 (human CMV strain AD 169 EcoRI-J fragment subcloned into pACYC184, Dr B Fleckenstein, Erlangen). Total plasmid DNA labelled with 35S-dCTP (NEN, specific activity 1200 Ci/mmol) by nick translation Exposure time 3-9 days. PCR with primers for IE-region After 35 cycles with a known copy number of plasmid DNA (see ISH) as few as 100 copies could be detected. Identity of ethidmm-bromide-stamed bands confirmed by Southern blotting and by hybridisation with 32P-labelled Internal ohgonucelotlde.8 CC=centnfugation culture (24 h co-culturing with human lung fibroblasts and detection of infection by indirect immunofluorescence using an anti-early [pp65 lower matrix protein] monoclonal antibody
*p
the best indicator of the efficacy of mean energy losses enzyme preparation:
patients total
In our the high
pancreatin replacement. were no
greater
on
expression after centifugation culture. Cells from seropositive and seronegative healthy donors and allograft recipients with or without CMV disease were used as controls. CMV infection was detected in mononuclear cells of only 1 of 21 healthy donors. Remarkably, in common variable immunodeficiency, CMV DNA was found in most patients and centrifugation culture supported the existence of CMV
acute
antigenaemia:
*Digestibility of total energy (as creon, pancrease HL). This study suggests that a considerable reduction in daily capsule intake can be achieved if the high enzyme preparation is used and this is welcomed by patients. The mean daily dose required was 2-8 to 1, close to the calculated ratio of 3 to 1. The variation in individual requirements means that this 1-for-3 advice is a guideline only; the ideal level of supplementation can be defined by the cumbersome and unpopular fat-balance studies (the limitations of which have been exposed by Murphy et all and confirmed by our own figures) or by patient satisfaction. All the patients in this study chose to continue on the high enzyme product.
(X2) versus healthy donors. ISH=m-situ DNA hybridisation with a CMV probe plasmid pCM 5018 (human CMV strain AD 169 EcoRI-J fragment subcloned into pACYC184, Dr B Fleckenstein, Erlangen). Total plasmid DNA labelled with 35S-dCTP (NEN, specific activity 1200 Ci/mmol) by nick translation Exposure time 3-9 days. PCR with primers for IE-region After 35 cycles with a known copy number of plasmid DNA (see ISH) as few as 100 copies could be detected. Identity of ethidmm-bromide-stamed bands confirmed by Southern blotting and by hybridisation with 32P-labelled Internal ohgonucelotlde.8 CC=centnfugation culture (24 h co-culturing with human lung fibroblasts and detection of infection by indirect immunofluorescence using an anti-early [pp65 lower matrix protein] monoclonal antibody
*p
